Back to Search Start Over

Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study.

Authors :
Ceccarelli G
Borrazzo C
Pinacchio C
Santinelli L
Innocenti GP
Cavallari EN
Celani L
Marazzato M
Alessandri F
Ruberto F
Pugliese F
Venditti M
Mastroianni CM
d'Ettorre G
Source :
Frontiers in nutrition [Front Nutr] 2021 Jan 11; Vol. 7, pp. 613928. Date of Electronic Publication: 2021 Jan 11 (Print Publication: 2020).
Publication Year :
2021

Abstract

Background: Mounting evidence suggests SARS-CoV-2 may impact on host microbiota and gut inflammation, infecting intestinal epithelial cells. This possible link and its implications can be investigated by observing the effects of modulation of the microbial flora in patients with COVID-19. The aim of this study was to compare the rate of mortality, the need of ICU hospitalization and the length of hospitalization in patients with severe COVID-19 pneumonia who received the best available therapy (BAT) vs. patients treated with BAT and supplemented with oral bacteriotherapy. Methods: This retrospective, observational cohort study included 200 adults with severe COVID-19 pneumonia. All patients received therapeutic regimens including low molecular weight heparin plus one or more between hydroxychloroquine, azithromycin, antivirals, and Tocilizumab. Oral bacteriotherapy was used as complementary treatment. Results: Out of the 200 patients, 112 received BAT without oral bacteriotherapy, and 88 BAT with oral bacteriotherapy. Crude mortality was 22%. Eleven percent died in the group of patients treated with BAT plus oral bacteriotherapy vs. 30% subjects in the group of patients managed only with BAT ( p < 0.001). By multivariate analysis, the age >65 years, CRP >41.8 mg/L, Platelets <150.000 mmc, and cardiovascular events were associated with the increased risk of mortality. Oral bacteriotherapy was an independent variable associated with a reduced risk for death. Despite large prospective trials are needed, this study highlights a possible role for oral bacteriotherapy in the management of patients hospitalized for COVID-19 pneumonia.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Ceccarelli, Borrazzo, Pinacchio, Santinelli, Innocenti, Cavallari, Celani, Marazzato, Alessandri, Ruberto, Pugliese, Venditti, Mastroianni and d'Ettorre.)

Details

Language :
English
ISSN :
2296-861X
Volume :
7
Database :
MEDLINE
Journal :
Frontiers in nutrition
Publication Type :
Academic Journal
Accession number :
33505983
Full Text :
https://doi.org/10.3389/fnut.2020.613928